Gilead submits Biologics Licence Application to USFDA for Bulevirtide
If approved, Bulevirtide will be the first treatment option for adult patients in the US with chronic Hepatitis Delta Virus…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
hepatitis delta virus
Gilead Sciences to acquire MYR GmbH
Gilead to acquire Hepcludex, a first-in-class entry inhibitor, for treatment of chronic hepatitis delta virus (HDV), after closing…